title: Clopidogrel vs. aspirin treatment on admission improves 5-year survival after a first-ever acute ischemic stroke. data from the Athens Stroke Outcome Project.
abstract: OBJECTIVE
  We undertook this study to compare the impact of aspirin vs. clopidogrel treatment on 5-year survival of patients experiencing a first-ever acute ischemic noncardioembolic stroke.
  
  
  METHODS
  This was a retrospective study involving patients with an acute ischemic stroke who had an indication for antiplatelet therapy (atherothrombotic, lacunar and cryptogenic stroke subtype). A total of 1228 (383 women) hospitalized due to an acute first-ever stroke and receiving aspirin (n = 880) or clopidogrel (n = 348) were finally involved. To determine the factors that independently predict 5-year survival statistical analysis including the Kaplan-Meier survival curve and multifactorial analysis (Cox regression) was performed.
  
  
  RESULTS
  Subjects treated with clopidogrel had improved 5-year survival compared with those receiving aspirin (log rank test: 16.4, p <0.0001). The difference in survival was evident as early as 6 months from index stroke: cumulative survival 93.8% for aspirin vs. 97% for clopidogrel (log rank test: 4.01, p = 0.045). The composite cardiovascular event (including stroke recurrence, myocardial infarction, unstable angina, coronary revascularization, aortic aneurysm rupture, peripheral atherosclerotic artery diseases, and sudden death) rates were lower in the clopidogrel group (n = 60, 17.2%) compared with the aspirin (n = 249, 28.3%) group (log rank test: 12.4, p <0.0001). This preferential effect of clopidogrel over aspirin was independent of age, gender, presence of cardiovascular disease other than stroke or cardiovascular risk factors as well as irrespective of the severity of stroke and days of hospitalization.
  
  
  CONCLUSIONS
  This study supports that clopidogrel is superior to aspirin in preventing death and cardiovascular events after an acute noncardioembolic ischemic stroke.
authors.affiliation: Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannnina, Greece. hmilioni@uoi.gr
authors.forename: Haralampos J
authors.initials: HJ
authors.lastname: Milionis
authors.forename: Grigorios
authors.initials: G
authors.lastname: Gerotziafas
authors.forename: Michael S
authors.initials: MS
authors.lastname: Kostapanos
authors.forename: Anastasia
authors.initials: A
authors.lastname: Vemmou
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Zis
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Spengos
authors.forename: Moses
authors.initials: M
authors.lastname: Elisaf
authors.forename: Konstantinos N
authors.initials: KN
authors.lastname: Vemmos
mesh_terms: D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D000077144:Clopidogrel; D005260:Female; D006115:Greece; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010343:Patient Admission; D012189:Retrospective Studies; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin